Key result
In hypertensive children and adolescents, logMMP-2 levels were independently associated with arterial stiffness (PWV z score) (β = 0.744; 95% CI 0.105-2.921; p < 0.05).
Why the study?
Matrix metalloproteinases may contribute to arterial stiffness via extracellular matrix remodeling, but their levels and associations with cardiovascular risk factors and arterial stiffness needed evaluation in pediatric high-risk groups.
Population
33 CKD patients, 18 type 1 diabetes patients, and 24 healthy controls
Comparison
Children with CKD vs type 1 diabetes vs healthy controls
Design
Cross-sectional study
Authors
Loading...
MMP levels may mark vascular risk in pediatric CKD and diabetes; leaves open biomarker utility pending prospective validation.
Cross-Sectional (n=75)
Effect estimate: β 0.744 (95% CI 0.105 to 2.921)
p-value: p=< 0.05
MMP-2 levels are elevated in children with CKD and associate with arterial stiffness in the presence of hypertension, suggesting a potential role in early vascular remodeling.
Stabouli et al. (2020) conducted a cross-sectional in Chronic kidney disease and type 1 diabetes (n=75). MMP-2 and MMP-9 levels vs. Healthy controls was evaluated on Arterial stiffness (PWV z score) (β 0.744, 95% CI 0.105 to 2.921, p=< 0.05). In hypertensive children and adolescents, logMMP-2 levels were independently associated with arterial stiffness (PWV z score) (β = 0.744; 95% CI 0.105-2.921; p < 0.05).